SLC5A2 and Hyperglycemia: The latter observation, that canagliflozin-induced protection in the nondiabetic rat, is particularly noteworthy: a clinically available SGLT2 inhibitor, canagliflozin, appears to have a cardiovascular and cardioprotective role that extends beyond (and probably also independent of) its intended indication in the management of hyperglycemia in type 2 diabetes mellitus.